Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oncternal Therapeutics Inc (ONCT)
NASDAQ:ONCT
RESEARCH TOOLSreports
Holding ONCT?
Track your performance easily
ONCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.32 - $13.14
Previous Close$1.46
Volume54.00K
Average Volume (3M)27.83K
Market Cap
$4.31M
Enterprise Value-$16.89M
Total Cash (Recent Filing)$21.43M
Total Debt (Recent Filing)$235.00K
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Nov 07, 2024EPS Estimate
-$3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.18
Shares Outstanding2,959,645
10 Day Avg. Volume127,066
30 Day Avg. Volume27,833
Standard Deviation0.25
R-Squared0.08
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.27
Price to Sales (P/S)2.21
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-7.92
Enterprise Value/Gross Profit-21.51
Enterprise Value/Ebitda0.61
Forecast
1Y Price Target
$10.00Price Target Upside575.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Oncternal Therapeutics News
PremiumCompany Announcements
Oncternal Therapeutics Restructures Amid Clinical Setbacks
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEnrollment has been completed and dosing initiated for the sixth dose cohort of ONCT-534, a dual-action androgen receptor inhibitor being tested in advanced prostate cancer patients.
Financial PerformanceOncternal Therapeutics reported a net loss that was narrower than expected, driven by greater-than-expected grant revenue.
Future OutlookONCT-534 is viewed as a potential driver of future upside to forecasts, even though it is not currently included in risk-adjusted revenues.
Bears Say
Clinical DataNegative clinical data for ONCT-808 in various combo studies.
Dilution RiskPossible near- to medium-term dilution risk affecting shareholder value.
Regulatory DecisionsNegative regulatory decisions impacting the stock.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ONCT FAQ
What was Oncternal Therapeutics Inc’s price range in the past 12 months?
Oncternal Therapeutics Inc lowest stock price was $1.32 and its highest was $13.14 in the past 12 months.
What is Oncternal Therapeutics Inc’s market cap?
Currently, no data Available
When is Oncternal Therapeutics Inc’s upcoming earnings report date?
Oncternal Therapeutics Inc’s upcoming earnings report date is Nov 07, 2024 which is in 50 days.
How were Oncternal Therapeutics Inc’s earnings last quarter?
Oncternal Therapeutics Inc released its earnings results on Aug 08, 2024. The company reported -$2.89 earnings per share for the quarter, beating the consensus estimate of -$3.033 by $0.143.
Is Oncternal Therapeutics Inc overvalued?
According to Wall Street analysts Oncternal Therapeutics Inc’s price is currently Undervalued.
Does Oncternal Therapeutics Inc pay dividends?
Oncternal Therapeutics Inc does not currently pay dividends.
What is Oncternal Therapeutics Inc’s EPS estimate?
Oncternal Therapeutics Inc’s EPS estimate is -$3.
How many shares outstanding does Oncternal Therapeutics Inc have?
Oncternal Therapeutics Inc has 2,959,645 shares outstanding.
What happened to Oncternal Therapeutics Inc’s price movement after its last earnings report?
Oncternal Therapeutics Inc reported an EPS of -$2.89 in its last earnings report, beating expectations of -$3.033. Following the earnings report the stock price went down -4.891%.
Which hedge fund is a major shareholder of Oncternal Therapeutics Inc?
Currently, no hedge funds are holding shares in ONCT
---
Oncternal Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (575.68% Upside)
$10.00 (575.68% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.21%
12-Months-Change
Fundamentals
Return on Equity
-118.06%
Trailing 12-Months
Asset Growth
-53.01%
Trailing 12-Months
Company Description
Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc. is a clinical-stage oncology company, which develops a diverse pipeline of treatments for cancers with critically unmet medical need. Its focus is on drug development on promising yet untapped biological pathways implicated in cancer progression. The company was founded in 1997 and is headquartered in San Diego, CA.
---
ONCT Earnings Call
Q2 2024
0:00 / 0:00
---
ONCT Stock 12 Month Forecast
Average Price Target
$10.00
▲(575.68% Upside)
Technical Analysis
Aclaris Therapeutics
―
ADC Therapeutics
―
Aptevo Therapeutics
―
Karyopharm Therapeutics
―
Best Analysts Covering ONCT
1 Year
1 Year Success Rate
0/9 ratings generated profit
1 Year Average Return
-77.53%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -77.53% per trade.
---